Opinion: My biggest GLP-1 ethical problem: patients who don’t want to stop
Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use
WEDNESDAY, Feb. 18, 2026 — The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the American Academy of…
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop
(MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill)
An $80-per-month produce prescription subsidy failed to improve cardiometabolic health…
Taking the next shot: GLP-1 research and the new era of weight loss
Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are now taking medications like Ozempic or Wegovy for weight loss or chronic conditions, and use is expected to keep rising.
STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more
The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews
Novo Nordisk to halve U.S. list price of Wegovy from 2027
Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday
What to Know About Trying to Conceive If You’re Taking a GLP-1
Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.
Satisfaction With Semaglutide Driven by Effective Weight Loss
FRIDAY, Feb. 20, 2026 — Satisfaction with semaglutide (Ozempic) is mainly driven by effective weight loss despite gastrointestinal side effects, according to a study published in the February issue of the Journal of Medical Internet…
Tirzepatide Use Linked to Lower Risk for Diabetic Retinopathy
FRIDAY, Feb. 20, 2026 — For patients with diabetes and overweight or obesity, tirzepatide use is associated with a lower incidence of new or progressive diabetic retinopathy (DR) and fewer complications, according to a study published online Jan…
Midsize Bodies Were Finally Going Mainstream—Then GLP-1s Came Along
Could weight-loss drugs shrink the body representation we’ve spent decades seeking?